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Abstract: The poxvirus vaccinia virus (VV) served as the model virus for which the first 
antivirals, the thiosemicarbazones, were identified. This dates back to 1950; and, although 
there is at present no single antiviral drug specifically licensed for the chemotherapy or  
-prophylaxis of poxvirus infections, numerous candidate compounds have been described 
over  the  past  50  years.  These  compounds  include  interferon  and  inducers  thereof  
(i.e.,  polyacrylic  acid),  5-substituted  2’-deoxyuridines  (i.e.,  idoxuridine),  IMP 
dehydrogenase inhibitors, S-adenosylhomocysteine hydrolase inhibitors, acyclic nucleoside 
phosphonates (such as cidofovir) and alkoxyalkyl prodrugs thereof (such as CMX001), viral 
egress inhibitors (such as tecovirimat), and cellular kinase inhibitors (such as imatinib). 
Keywords:  thiosemicarbazones;  interferon  (inducers);  idoxuridine  (IDU);  acyclic 
nucleoside  phosphonates;  cidofovir;  CMX001  (HDP-CDV);  tecovirimat  (ST-246);  
Gleevec (imatinib) 
 
1. Introduction: The thiosemicarbazones 
In 1972, D.J. Bauer stated in his “Introduction to Antiviral Chemotherapy” [1] that the first true 
antiviral  agents  discovered  were  the  thiosemicarbazones.  They  were  introduced  into  medicine  by 
Domagk et al. [2], as active against tubercle bacilli. As stated by Bauer [1], “the discovery of an agent 
effective in one branch of microbiological science is usually followed by its trial in other branches”, 
and  so,  p-aminobenzaldehyde  thiosemicarbazone  was  the  first  antiviral  agent,  found  in  1950  by 
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Hamre, Bernstein and Donovick [3] to be active against vaccinia virus (VV) infection in fertile eggs 
and mice. This observation was confirmed by Hamre, Brownlee and Donovick in 1951 [4]. Thompson, 
Price  and  Minton  [5]  then  showed  that  benzaldehyde  thiosemicarbazone  protected  mice  infected 
intracerebrally with VV. 
An example of virus plaque inhibition (in HeLa cells), a technique as originally applied in these 
early  days  [1],  illustrates  the  central  disc  containing  a  compound  having  activity  against  rabbit 
poxvirus (Figure 1). The compound has diffused through the agar overlay, and the disc is surrounded 
by a zone where the formation of plaques is inhibited. Which compound inhibited rabbit poxvirus 
plaque formation is not clear from the context.  
Figure  1. Plaque-inhibition test. The central disc contains a compound having activity 
against rabbitpox virus. The compound has diffused through the agar overlay and the disc 
is surrounded by a zone in which the formation of plaques has been inhibited. Figure taken 
from Bauer [1]. 
 
 
In  his  paper  on  “Thiosemicarbazones”  [6],  Bauer  contended  that  the  benzaldehyde 
thiosemicarbazones were the first true antiviral agents to be discovered and that “they could have 
yielded  antiviral  agents  useful  in  human  medicine  if  their  development  had  not  come  to  a  halt”. 
Thompson et al. [7] then described a wide range of thiosemicarbazones, from which emerged isatin  
3-thiosemicarbazone [8]. This compound was further studied by Bauer [9] and found to be effective 
against  the  multiplication  of  VV  in  mice  infected  intracerebrally.  The  thiosemicarbazone  finally 
selected for use in man was 1-methylisatin 3-thiosemicarbazone, better known as methisazone (brand 
name: Marboran). For the structural formulae of the compounds, see the Appendix accompanying this 
article. As further documented by Bauer [1], methisazone had tentative efficacy in the treatment and 
prophylaxis of smallpox, and the treatment of the complications of smallpox vaccination, i.e., eczema 
vaccinatum and vaccinia gangrenosa. Methisazone would have yielded better results than antivaccinial 
-globulin in the prophylaxis of smallpox in persons who had been in contact with variola virus [10]. 
However, with the imminent global eradication of the variola virus (resulting from the successful 
implementation  of  the  smallpox  vaccination),  interest  in  the  use  of  methisazone  for  both  the Viruses 2010, 2                                       
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prophylaxis or treatment of smallpox rapidly declined, and so did the interest in further developing 
antiviral compounds active against either variola or vaccinia virus. 
2. The VV pox tail lesion model: the simplest virus mouse model ever described 
Vaccinia virus (VV) was the first virus I worked with when joining the Laboratory of my master, 
Prof. P. De Somer in 1964, as a student in medicine, to work on interferon and inducers thereof. 
Vaccinia virus was at that time not the highest priority as a target virus for antiviral development, but it 
was a useful tool virus for titrating interferon, not dangerous as we were all vaccinated with the virus, 
and extremely stable and reliable as a challenge virus, i.e., for interferon titrations in murine L929 
cells, which at that time I did almost weekly. Then I found VV to be a most useful virus to demonstrate 
the efficacy of interferon and interferon inducers [such as polyacrylic acid (PAA)], even if the latter 
was administered four weeks before VV infection (Table 1) [11]. The model was simple and reliable: 
at 7-10 days after intravenous injection with VV, the mice developed tail lesions which could be easily 
counted, and the reduction in the tail lesion number could be interpreted as a quantitative measure of 
the antiviral activity of any given anti-VV agent. The model was first described by Boyle, Haff and 
Stewart [12], but I found it extremely useful, convenient and accurate to demonstrate in vivo anti-VV 
activity of interferon and interferon inducers [11], and of many nucleoside analogs as well, including 
ribavirin,  and  5-substituted  2’-deoxyuridines  [13],  carbocyclic  3-deazaadenosine  [14],  
3’-fluoro-3’-deoxyadenosine [15], (S)-HPMPA [16], EICAR [17], and S2242 [18]. The VV pox tail 
lesion model has also been used by others [19-21] to demonstrate the anti-VV activity of a variety of 
compounds  (as  reviewed  by  Smee  and  Sidwell  [22]),  but,  despite  (and  probably  because  of)  its 
simplicity, the VV pox tail lesion model has since the review article of Smee and Sidwell [22] in 2003 
no longer popped up in recent publications. 
Table  1.  Effect  of  time  of  a  single  polyacrylic  acid  (PAA)  dose  on  the  formation  of 
vaccinia virus tail lesions. Data taken from De Clercq and De Somer [11]. 
PAA treatment
a 
before vaccinia 
virus infection
b 
No. of lesions  Probability (comparison 
with control group) 
  Per individual mouse  Average   
Control  9, 3, 8, 1, 6, 2, 5, 11, 4, 0, 3, 2, 0, 11, 15, 
10, 30, 4 
6.89   
4 weeks before  0, 1, 0, 5, 1, 0, 2, 0, 3, 1, 0, 2, 1, 3, 0, 11, 
4, 3, 7, 1, 0 
2.14  0.005 < P < 0.01 
3 weeks before  0, 0, 1, 3, 5, 3, 0, 0, 0, 9, 3, 1, 0, 0, 1  1.73  0.01 < P < 0.02 
2 weeks before  3, 1, 2, 1, 2, 1, 6, 1, 0, 0, 0, 1, 2, 1  1.50  P ~ 0.01 
1 week before  0, 1, 1, 0, 0, 3, 2, 1, 1, 0, 2, 2, 1, 0, 1  1.00  0.001 < P < 0.002 
aPAA (0.25 mg) injected intraperitoneally.
 bVaccinia virus injected intravenously.  Viruses 2010, 2                                       
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3. 5-Substituted 2’-deoxyuridines 
The  5-substituted  2’-deoxyuridines  idoxuridine  (5-iodo-dUrd,  5-iodo-2’-deoxyuridine,  IDU)  and 
trifluridine (5-trifluoro-2’-deoxythymidine, 5’-trifluoromethyl-dUrd, TFT) have been generally viewed 
as initiating the dawn of antiviral therapy, now 50 years ago [23]. In essence, this is because IDU and 
TFT later became the first licensed antiviral agents approved for the topical treatment (as eye drops 
and/or ointment) of herpetic keratitis [due to herpes simplex virus (HSV)]. It should not be ignored, 
however, that, while Prusoff [24] was the first to describe the synthesis of IDU, Herrmann [25] and 
Kaufman,  Nesburn  and  Maloney  [26]  were  the  first  to  describe  the  inhibitory  effects  of  IDU  on 
vaccinia virus plaque formation in chick embryo cell cultures in vitro [25], and vaccinia virus infection 
of the rabbit cornea in vivo [26]. In fact, IDU and TFT would only be the first of a long list of  
5-substituted 2’-deoxyuridines [27,28], which also included 5-nitro-dUrd [29], 5-formyl-dUrd [30], 
and  5-ethyl-dUrd,  5-vinyl-dUrd  and  5-ethynyl-dUrd  [31],  and  which  were  all  shown,  in  1980,  to 
inhibit VV replication in primary rabbit kidney cell cultures in vitro at an IC50 in the 0.1-1 µg/ml 
concentration range [31]. Ten years earlier, in 1969, Swierkowski and Shugar [32] had pointed to the 
importance of 5-ethyl-2’-deoxyuridine as an antiviral agent because it was considered nonmutagenic 
(in contrast with 5-iodo- and 5-bromo-2’-deoxyuridine). In 1965, Nemes and Hilleman [33] [the same 
Maurice Hilleman as magnificently depicted by Paul A. Offit in his book “Vaccinated. One Man’s 
Quest to Defeat the World’s Deadliest Diseases” [34]] described the effective treatment of herpetic 
keratitis  with  the  new  5-substituted  2’-deoxyuridine  5-methylamino-2’-deoxyuridine  (MADU);  the 
antiviral activity of MADU roughly approximated that of IDU [33], but the tests were done with HSV, 
not VV. The largest series of 5-substituted 2’-deoxyuridines ever reviewed for their antiviral activity 
was that published in Mike Harnden’s book [35], but while the compounds were evaluated for their 
comparative activity against both HSV-1 and HSV-2, no data for VV were included [35]. 
Of the 5-substituted dUrd analogs, only  IDU has  been subject of an  in-depth evaluation  of its 
efficacy against VV infections in mice [36]. IDU had a protective effect in the VV tail lesion model 
(see  supra)  in  immunocompetent  mice,  and  in  a  lethal  model  for  VV  infection  in  SCID  (severe 
combined  immune  deficiency)  mice  that  had  been  infected  with  VV  either  intranasally, 
intraperitoneally or intravenously [36], but the dose at which IDU had to be given (subcutaneously) 
was relatively high (75-150 mg/kg/day), and when IDU was compared to cidofovir [(S)-HPMPC], the 
latter  proved  more  efficacious  at  a  lower  dose  (25  mg/kg/day)  in  its  protective  activity  against 
intranasal VV infection in SCID mice [36]. 
4. Nucleoside analogs other than IDU and 5-substituted dUrd analogs 
In addition to the 5-substituted 2’-deoxyuridines, numerous other nucleoside analogs have been 
reported to inhibit VV at a sufficiently low IC50 (<1 µg/ml) to be potentially useful from a therapeutic 
viewpoint  [27]:  i.e.,  IMP  (inosine  5’-monophosphate)  dehydrogenase  inhibitors,  such  as  EICAR  
(5-ethynyl-1--D-ribofuranosylimidazole-4-carboxamide)  [17];  SAH  (S-adenosylhomocysteine 
hydrolase)  inhibitors,  such  as  neplanocin  A  [37],  3-deazaneplanocin  A  [21],  
9-(trans-2’,trans-3’-dihydroxycyclopent-4’-enyl)adenine  (DHCeA)  and  -3-deazaadenine  (c
3DHCeA) 
[39],  (1’R,2’S,3’R)-9-(2’,3’-dihydroxycyclopentan-1’-yl)adenine  (DHCaA)  and  -3-deazaadenine Viruses 2010, 2                                       
 
 
1326 
(c
3DHCaA)  [40],  (±)-6’-fluoroaristeromycin  (F-C-Ado)  [41],  (±)-5’-noraristeromycin  [42],  
(-)-5’-noraristeromycin  [43],  epi(-)-5’-noraristeromycin  [44],  (-)-3-deaza-5’-noraristeromycin  [45], 
(R)-6’-C-methylneplanocin  A  [46],  6’-homoneplanocin  A  [47],  and  2-fluoroneplanocin  A  [48]; 
carbocyclic  cyclopentenyl  cytosine  (Ce-Cyd)  [49,50],  a  putative  inhibitor  of  CTP  synthetase;  
8-methyladenosine [51], whose mechanism of action as an inhibitor of VV has never been clarified; 
the  N-7-substituted  acyclic  nucleoside  analog  2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine 
S2242 [52], which is inhibitory to VV, as well as various herpesviruses (HSV, VZV, CMV), and 
whose antiviral activity, while depending on phosphorylation by deoxycytidine kinase (dCK) [53], was 
never  fully  elucidated;  and  adenine  arabinoside,  vidarabine  (ara-A),  the  first  antiviral  drug  to  be 
approved for systemic use (for the treatment of VZV infections) [54], which is quite effective against 
VV  replication  in  vitro  [31]  (the  inhibition  of  VV  replication  by  ara-A  may  be  explained  by  the 
inhibitory effect of ara-ATP on viral DNA synthesis and/or a direct inhibitory effect of ara-A on SAH 
hydrolase, akin to that of all other adenosine analogs mentioned above (see supra). 
Figure 2. Large zone of inhibition without zone of toxicity. Cultures of chick fibroblast 
cells  were  seeded  with  approximately  500  plaque-forming  units  of  vaccinia  virus;  the 
cylinder(s)  were  charged  with  0.05  ml  of  solution  of  the  substance  tested  (6-azauracil 
riboside))  (2.0  M);  dishes  of  4  cm  diameter  were  employed.  Figure  taken  from  Rada, 
Blaškovič, Šorm and Škoda [57].  
 
 
Of the compounds listed above, very few were further explored for their in vivo activity against VV 
infection, and, when this was done, uniformly the pox tail lesion model was used: hence, this model 
allowed demonstration of the in vivo efficacy of EICAR [17], S2242 [18] and 3-deazaneplanocin A 
[21]. When no further in vivo testing was done with most of the compounds showing sufficient potency 
against VV in vitro, this must be attributed to the paucity of material available for such in vivo testing. 
In part C of my Stories in Antiviral Drug Discovery [55] I wrote that the first description of the 
antiviral activity of 6-azauridine dated back to 1977, thereby referring to the paper published by Rada 
and Dragun in Ann. N.Y. Acad. Sci. [56]. This is not entirely correct. Rada, Blaškovič, Šorm and Viruses 2010, 2                                       
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Škoda in 1960 (that is one year before Herrmann reported the plaque inhibition test for demonstrating 
the inhibitory effect of IDU on VV and HSV [25]) published a brief report in Experientia [57] on the 
inhibitory effect of 6-azauracil riboside on the multiplication of vaccinia virus (Figure 2). Rada et al. 
[57] also stated that 6-azauracil riboside had no direct inactivating effect on vaccinia virus and had no 
inhibitory effect on the multiplication of influenza virus, Newcastle disease virus (NDV) and Eastern 
equine encephalomyelitis virus when tested by the plaque method [57]. The mechanism of antiviral 
action of 6-azauridine was never fully elucidated. It has been assumed to interact, like pyrazofurin, at 
the level of the OMP decarboxylase [55]. 
5. The acyclic nucleoside phosphonates 
In 1986, we (Antonin Holý and I, and our colleagues) described the broad-spectrum anti-DNA 
virals,  including  anti-VV,  activity  of  (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine  
[(S)-HPMPA]  [58],  and  one  year  later,  we  extended  these  observations  to  various  other 
phosphonylmethoxyalkyl  derivatives  of  purines  and  pyrimidines,  i.e.,  (S)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine [(S)-HPMPC] [59] [(S)-HPMPC (cidofovir, Vistide®) would be 
licensed nine years later, in 1996, for the treatment of CMV retinitis in AIDS patients]. From the 
beginning, it was immediately clear that (S)-HPMPA and especially (S)-HPMPC (because it seemed to 
be  less  toxic  in  mice)  had  therapeutic  potential  as  antiviral  drugs  [60].  The  in  vivo  activity  of  
(S)-HPMPA in the VV pox tail lesion model was already mentioned in the paper published in Antiviral 
Research in 1987 [59]. For (S)-HPMPC, we first focused on its efficacy in the therapy of experimental 
HSV  infections  in  mice  [61],  before  we  described,  in  1993,  its  efficacy  in  the  treatment  of  VV 
infections in both normal, immunocompetent mice (based, again, on the VV pox tail lesion model) and 
immunodeficient (SCID) mice [62]. 
This was five years before orthopoxviruses, in particular variola, the etiological agent of smallpox, 
were,  rather  suddenly,  felt  as  a  bioterrorist  public  health  threat  [63,64].  This  bioterrorist  scenario 
prompted the search for an adequate therapy (or prophylaxis) to curb orthopoxvirus infections, and in 
the next few years several investigators (Bray et al., Smee et al.) found (S)-HPMPC (in the mean time 
better known as cidofovir) to protect mice against lethal respiratory infections with cowpox virus 
[65,66]  and  vaccinia  virus  [67,68].  Aerosolized  cidofovir  was  found  to  be  efficacious  against 
aerosolized cowpox virus infection in mice [69], and cidofovir also proved efficacious in the treatment 
of  mice  infected  with  an  highly  virulent  strain  of  ectromelia  (mousepox  virus)  encoding  
interleukin-4 [70]. 
In a review on the potential of cidofovir in the treatment of poxvirus infections [71], I stated that 
cidofovir  should  be  effective  in  the  therapy  and  short-term  prophylaxis  of  smallpox  and  related 
poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise 
in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia). With 
Johan Neyts and colleagues, I later demonstrated that cidofovir is indeed efficacious in the treatment of 
disseminated progressive vaccinia (in a mouse model); even when cidofovir treatment was initiated at 
the time disseminated vaccinia had developed, it caused lesions to heal and regress (Figure 3) [72,73].  
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Figure 3. Effect of systemically administered cidofovir on disseminated vaccinia when 
therapy was initiated on day 15 p.i. (A) Progression of cutaneous vaccinia in three mock-
treated animals. Mice 1 and 3 died on day 35 p.i.; mouse 2 died on day 36 p.i. (B) Effect of 
subcutaneous treatment with  cidofovir (at 100 mg/kg/day), initiated  on day  15 p.i.,  on 
disseminated cutaneous vaccinia lesions. Cidofovir was given for 21 days (over a period of 
24 days). Figure taken from Neyts, Leyssen, Verbeken and De Clercq [72,73]. 
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6. Oral alkoxyalkyl prodrugs of acyclic nucleoside phosphonates 
An additional advantage of cidofovir is that it is not only active against orthopoxviruses, but also 
parapoxviruses  [such  as  orf  (ecthyma  contagiosum)]  and  molluscipoxviruses  (such  as  molluscum 
contagiosum), which may both lead to serious infections in immunocompromised patients (in fact, 
anecdotal  reports  suggest  that  cidofovir  is  clinically  efficacious  against  orf  and  molluscum 
contagiosum  [71,74,75]).  However,  cidofovir,  like  all  other  acyclic  nucleoside  phosphonates  [76], 
suffers  from  the  disadvantage  that  it  has  poor  oral  bioavailability.  This  explains  why  alkoxyalkyl  
[i.e., hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE)] prodrugs of cidofovir (HDP-CDV and 
ODE-CDV) were developed [77], intentionally as oral medicines for the prophylaxis and therapy of 
smallpox infection [78]. Esterification of cidofovir with alkoxyalkanols not only increases its oral 
bioavailability  but  also  diminishes  drug  accumulation  in  the  kidney  [79],  and  thus  reduces 
nephrotoxicity [77]. In molecular terms, HDP-CDV is rapidly taken up in the cells thanks to a rapid 
association  with  cellular  membrane  phospholipids  [80].  This  results  in  enhanced  inhibition  of 
orthopoxvirus (i.e., vaccinia virus and cowpox virus) replication in vitro [81,82]. Increased in vivo 
activity of HDP-CDV and ODE-CDV, over that of CDV, has also been demonstrated in mice infected 
with vaccinia virus (VV) or cowpox virus (CV) [83], or ectromelia (mousepox) virus [84]. 
Following the same reasoning as for cidofovir, alkoxyalkyl (i.e., HDP and ODE) derivatives have 
also been prepared from (S)-HPMPA, the prototype of the acyclic nucleoside phosphonates [58]. When 
compared  with  the  alkoxyalkyl  esters  of  cidofovir,  the  corresponding  alkoxyalkyl  esters  of  (S)-
HPMPA were equally active against CMV but were 15- to 20-fold more active against VV and CV in 
vitro [85]. In vivo, oral treatment with HDP-(S)-HPMPA or ODE-(S)-HPMPA were highly effective 
against lethal VV or CV infections in mice [86]. Thus, alkoxyalkyl prodrugs of both cidofovir and  
(S)-HPMPA  can  be  considered  excellent  candidates  for  the  oral  treatment  (and  prophylaxis)  of 
smallpox in humans, should this prove necessary in the event of a bioterrorist release of the variola 
virus (HDP-CDV is also referred to as CMX001 [78]). 
7.  ST-246,  an  orally  bioavailable  antipoxvirus  compound,  that  inhibits  extracellular  virus 
formation 
Following  a  totally  new  strategy  (different  from  the  nucleoside  or  nucleotide  analogs),  Dennis 
Hruby and his colleagues at SIGA Technologies in Corvallis (Oregon) came up with a new class of 
orthopoxvirus (i.e., vaccinia virus) antiviral drugs (i.e., TTP-6171) that block viral maturation [87]. 
These drugs block viral maturation through an interaction with the VV I7L gene product, a cysteine 
proteinase responsible for cleavage of the three major core protein precursors [88] and, hence, the 
production of infectious virions [89]. The reported compound, TTP-6171, was not further pursued as a 
potentially antiviral drug, in favor of a newly discovered compound, ST-246, that appeared to inhibit 
extracellular orthopoxvirus formation (and to protect mice from a lethal orthopoxvirus challenge) [90], 
apparently as the result of an action targeted at the F13L protein (phospholipase) which had previously 
[91] been recognized as a major membrane component of extracellular vaccinia virus. 
ST-246,  or  4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-etheno-cycloprop-
(f)isoindol-2-(1H-yl)benzamide [92] was shown to have activity against a number of orthopoxviruses, Viruses 2010, 2                                       
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including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox) and variola virus [90]. ST-
246 has proven effective against vaccinia, cowpox, and camelpox viruses in human embryonic lung 
and  primary  human  keratinocyte  cell  monolayers,  as  well  as  three-dimensional  organotypic  raft 
cultures [93]. In vivo efficacy of ST-246 has been demonstrated in mice infected with vaccinia virus 
[90] or ectromelia virus (even if treatment was delayed until 72 hours after virus infection [94]), and in 
ground squirrels infected with monkeypox virus [95]. ST-246 is also effective against aerosolized 
rabbit pox in rabbits [96], and acts synergistically with CMX001 (HDP-CDV) in mice infected with 
cowpox virus [97], which opens new avenues for the treatment of orthopoxvirus infections. 
Most important is to know whether ST-246 would be effective against smallpox (bioterrorist attack) 
or the complications of smallpox vaccination (such as eczema vaccinatum). A recent case of severe 
eczema vaccinatum in a household contact (28-month-old son) of a smallpox vaccinee illustrates the 
risks for such adverse events [98]. The boy eventually recovered after treatment with vaccinia immune 
globulin, cidofovir, and ST-246 [98]. What exactly saved the boy’s life - the antibody, cidofovir, ST-
246, or the extraordinary medical care, or combinations of some or all of the above - would never be 
known. 
Recently,  ST-246  has  been  found  to  protect  non-human  primates  from  smallpox  virus  or 
monkeypox virus [99]. ST-246 has, in the mean time, been renamed tecovirimat [100] and its target 
protein, F13L, is also known as p37. It is further developed by SIGA Technologies for the treatment of 
variola virus infection (smallpox) [100]. 
8. Cellular kinases as targets for anti-orthopoxvirus therapy 
Among  the  various  agents  that  could  be  considered  potentially  useful  in  the  therapy  of 
(ortho)poxvirus infections [101], also rank a few compounds that are targeted at cellular (tyrosine) 
kinases, and thus could inhibit poxvirus infections through inhibition of cellular signal transduction, 
i.e., CI-1033 and related 4-anilinoquinazolines [102] and STI-571 (imatinib, better known as Gleevec 
or Glivec) [103]. Gleevec has been licensed for clinical use as an anticancer agent, to treat chronic 
myeloid leukemia. That it would also have the ability to inhibit poxvirus infections (by blocking the 
egress of these viruses from infected cells) [103] is an unanticipated attribute [104]. Thus, Gleevec 
casts “a pox on poxviruses” [104], but although the findings of Reeves et al. [103] date from five years 
back,  the potential  utility of Gleevec, or  tyrosine  kinase inhibitors in general,  in the treatment  of 
poxvirus infections like smallpox, monkeypox, or the complications associated with vaccinia virus 
vaccination, still remains to be substantiated. 
9. Camelpox virus, the orthopoxvirus most closely related to variola virus 
Of all the (ortho)poxviruses, camelpox virus, the etiologic agent of camelpox occurring in Old 
World  camels  (Camelus  dromedarius  and  Camelus  bactrianus),  is  the  orthopoxvirus  most  closely 
related  to  variola  virus,  the  cause  of  smallpox  [105].  Studies  with  camelpox  virus  (which  is  not 
supposed to be pathogenic for humans) have allowed confirmation of the anti-poxvirus activity of the 
“older”  acyclic  nucleoside  phosphonates  such  as  (S)-HPMPA  and  (S)-HPMPC  [106],  but  also  to 
extend  the  anti-camelpox  virus  activity  to  the  “newer”  acyclic  nucleoside  phosphonates  such  as  
(R)-{2,4-diamino-3-hydroxy-6-[2-(phosphonomethoxy)propopy]}pyrimidine [(R)-HPMPO-DAPy] and Viruses 2010, 2                                       
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1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine  (HPMP-5-azaC)  [107].  As  already 
mentioned above [93], the anti-(ortho)poxvirus activity of ST-246 also extends to camelpox virus, 
although camelpox, vaccinia, and cowpox show different levels of sensitivity to ST-246, probably 
because of dissimilarities between their ways of propagation [108]. 
10. Epilogue: antiviral treatment more effective than smallpox vaccination 
Figure 4. Kaplan-Meier plot showing the effect of different post-exposure treatments on 
the  survival  of  monkeys.  Survival  expressed  as  percentages  after  intratracheal  MPXV 
infection. After virus exposure, macaques were sham-treated (group I), vaccinated with 
smallpox vaccine Elstree-RIVM (group II), treated with 5 doses of cidofovir (group III), 
with six doses of cidofovir (group IV), with five doses of HPMPO-DAPy (group V) or 
with six doses of HPMPO-DAPy (group VI). Arrowheads indicate times of vaccination 
and antiviral treatment. *The control group is supplemented with 11 animals from previous 
experiments. Figure taken from Stittelaar et al. [109]. 
 
 
Although the preventive use of smallpox vaccination is well documented, little is known about its 
efficacy when used after exposure to variola virus. A few years ago, we (Albert Osterhaus and I, and 
our  colleagues)  wanted  to  compare  the  effectiveness  of  post-exposure  smallpox  vaccination  and 
antiviral treatment with either cidofovir [(S)-HPMPC] or the related acyclic nucleoside phosphonate 
analog (R)-HPMPO-DAPy, at 24 hours after lethal intratracheal infection of cynomolgus monkeys 
(Macaca fascicularis) with monkeypox virus. This study was actually planned after I had met Koert 
Stittelaar at a meeting in London (“Twenty-five years on: smallpox revisited”, Retroscreen Virology 
and Institute of Cell and Molecular Sciences Barts and the London Queen Mary’s School of Medicine 
& Dentistry, The Great Hall, St. Bartholomew’s Hospital, London, Great Britain, 31 October 2003). Viruses 2010, 2                                       
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This study, published in 2006 in Nature [109] clearly revealed that initiation of antiviral treatment with 
either  cidofovir  or  (R)-HPMPO-DAPy  at  24  hours  after  monkeypox  virus  infection  resulted  in 
significantly reduced mortality (Figure 4). In contrast, when monkeys were vaccinated at 24 hours 
after  virus  infection,  using  a  standard  human  dose  of  a  currently  recommended  smallpox  vaccine 
(Elstree),  no  significant  reduction  in  mortality  was  observed  [109].  From  this  study  [109],  we 
concluded “that adequate preparedness for a biological threat involving smallpox should include the 
possibility  of  treating  exposed  individuals  with  antiviral  compounds  such  as  cidofovir  or  other 
selective anti-poxvirus drugs”. 
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